Objective: Hereditary angioedema (HAE) is a rare autosomal-dominant disease characterized by recurring attacks of nonpruritic, nonpitting edema caused by an inherited deficiency or dysfunction in the C1 esterase inhibitor (C1 INH). Symptoms present years before an accurate diagnosis is made. Our aim was to determine the prevalence and clinical manifestations of HAE in untested blood relatives of HAE index patients in a city of Düzce province, Turkey.
INTRODUCTION
Hereditary angioedema (HAE) is a rare autosomal dominant disease caused by an inherited deficiency or dysfunction of the plasma protein C1 esterase inhibitor (C1 INH). It is characterized by recurring attacks of nonpruritic, nonpitting subcutaneous edema, or submucosal edema of the small/large intestines or upper/ lower airways (1) . Symptoms typically present during childhood; however, the diagnosis could be delayed for a decade or more, even in developed countries (2) (3) (4) (5) . The offspring (children) of a diseased parent with a mutation of the C1 INH gene will have a 50% chance of inheriting the HAE disorder. Because of the scarcity of the disease, clinicians do not think of HAE in the first plan of their differential diagnosis (6) . Additionally, despite its high probability due to familial predisposition, many family members of HAE patients are not searched for the disease. With new and effective therapeutic products, screening of family members has increasingly been given emphasis as a means to diminish the significant morbidity and mortality related to HAE (7) .
Aim
This study was designed to determine the prevalence and occurrence of clinical manifestations of hereditary angioedema (HAE) in previously unevaluated blood relatives of known (index) patients with HAE in a few villages of a city in a province (Düzce) in Turkey.
METHODS

Study Design
In the beginning, after this study was approved by the relevant ethics committee (number: 162 214 662/050.01.04/90), we informed the local administration about our survey and got their approval as well. Later, we reached out to the recorded 4 (index) cases diagnosed with HAE and their untested relatives. A pedigree drawing was performed for the 4 index cases diagnosed with HAE ( Figure 1 ). In addition, through public meetings with the permission of the local administration, the patients and relatives were informed about the disease. Besides close relatives of the index cases, distant relatives of the index case were also of interest. Close and distant blood relatives that wanted to enroll in the study were identified. These patients and their relatives were first informed of the nature of the study by telephone and were then visited. During this visit, the untested relatives were given a questionnaire ( Table 1) . The questionnaire was used to collect information on the demographics, screening status of blood relatives according to the HAE index patient, pregnancy, medication use, and past medical history including specific questions about swelling and symptoms that could be consistent with an angioedema attack. During the visit, permission by filling the informed consent form was obtained from all the blood relatives of the 4 index cases who agreed to enroll in the study. During this visit, after completing the questionnaire, blood samples were drawn and complement tests were performed to verify the diagnosis. If the complement testing (C4, C1 INH antigen level, and C1 INH activity) was normal in a suspected person, the diagnosis of HAE was excluded, and the results were provided to them. If the complement test results were abnormal or HAE could not be ruled out, the subjects were telephoned. They were asked the same questionnaire about the symptoms of HAE, the time of the onset of symptoms, swelling attacks, and drug use, and new complement testing was planned. In addition, through correspondence with the local health authorities, the medical/laboratory records of the newly diagnosed HAE patients were passed to their family physicians. (A diagram of participation from the index cases to the identification of untested relatives with laboratory results compatible with the diagnosis of HAE is shown in Figure 2 ).
Complement Tests
Fresh serum blood samples were collected in a red top Vacutainer tube for complement testing. Within six hours of blood collection, 3 mL of serum from the untested relatives was obtained and stored at −20°C. Frozen serum samples were tested within 72 hours for C4, antigenic and functional C1 INH levels. C4 was evaluated using the Cobas C4-2 kit (Roche, 
Questionnaire
Questions were developed by collaborating with HAE experts to characterize the current state of screened subjects for HAE disorder. Nine questions were categorized into several broad areas, including patient characteristics, burden of disease, and treatment options (Table 1) .
Statistical Analysis
Data from our study group were pooled and presented as descriptive (summary) statistics using the IBM Statistical Package for the Social Sciences 21.0 (IBM Statistics; Armonk, NY, USA) software package program in the form of group means, rates, and proportions.
RESULTS
Demographics
One hundred and eighteen blood relative subjects were identified from pedigree charts of 4 index patients with HAE. Nine out of 118 blood relatives of HAE patients had already died. Six of them were diagnosed with HAE before death. From the remaining 109 living relatives, 64 (including 4 index cases) elected to enroll in the study and underwent complement testing. Fortyfive untested blood relatives did not want to enroll in the study. Twenty-nine enrolled blood relatives (29/60: 48.3%) were female, and 31/60 (51.6%) of them were male. The median age of all untested subjects, including the index cases, was 41 (range: 4-75) years ( Table 2) .
Prevalence of HAE in Close and Distant Relatives C1 INH antigen levels were significantly low in 22/60 (36.6%) of the untested blood relatives of 4 index patients. These subjects were thought to have Type 1 HAE disorder. The C1 INH activity was significantly low in just 1/60 (1.6%) untested subject. This one was thought to have Type 2 HAE disease. In the remaining 4 subjects, HAE could not be ruled out during the study due to borderline low complement results. These suspicious results will be repeated in the near future. As a result, of the 60 relatives who enrolled in the study and underwent complement testing, 36.6% of them were found to have laboratory results indicative of Type 1 and 1.6% of them has results indicative of type 2 HAE. The complement tests could not rule out the diagnosis of HAE (indeterminate cases) in 4 patients (4/60: 6.6%). In 33/60 (55%) of the untested blood relatives, the HAE disorder was ruled out ( Table 2 ).
The median age of the 4 patients (indeterminate cases) whose complement tests could not rule out the diagnosis of HAE was 33.5 (range: 4-71) years. The mean C1 INH protein levels of these subjects was detected as 0.17±0.01 g/L (0.20, 0.15, 0.17, and 0.17 g/L). The C1 INH activity and C4 levels were within normal limits. There was not a symptom that might have been related to HAE in the indeterminate cases. This suggests that indeterminate cases/subjects might need some more time to develop symptoms since the median age of the 9 symptomatic patients was 42 years. Complement testing of these patients will be performed again.
According to the index cases, 10/23 newly diagnosed patients (43.5%) were first-degree relatives and 13/23 (56.5%) of them were more distant (second/third degree) relatives. In the 60 subjects who enrolled in our study, 17 of them were first-degree relatives, and the remaining 43 were more distant relatives. The HAE diagnosis rate in the first degree relatives of the index cases was 58.8% (10/17), and it was 30.2% (13/43) in the more distant relatives ( Table 2) .
History of Symptoms
Of 23 (22; type 1+1; type 2) newly diagnosed subjects, 9 (39.1%) subjects reported symptoms that may be related to HAE, such as swelling in the face, genitourinary region or extremities, and abdominal pain. These 9 symptomatic patients reported a few swelling episodes per year persisting for a couple of days. The attacks were mostly reported to be triggered by stress and/ or trauma. Most of the 9 patients did not recall the time when the first attack happened. Swelling in extremities was observed in 5 (55.5%) of them, swelling in the face (lip) was reported in 4 (44.4%), swelling in the testis in 1 (11.1%), and abdominal pain was reported in 3 (33.3%) of them ( Figure 3) . The median age of the 9 symptomatic patients was 42 (range: 25-75) years, whereas the newly diagnosed asymptomatic subjects had a median chronological age of 17 (range: 9-74) years (Table 2) .
DISCUSSION
Hereditary angioedema (HAE), caused by C1-INH deficiency, is a rare disease with an estimated frequency of 1:10.000-1:150.000 (11, 12) . The clinical features of HAE consist of recurrent episodes of edema, which usually last for 2-5 days. The skin, gastrointestinal tract, and upper airway are most commonly affected in the recurrent edema attacks (13) . A diagnosis of HAE should be suspected in any patient with recurrent angioedema attacks on the skin as well as upper airways or abdominal pain. There have also been recent reports of attacks manifesting as headaches, temporary neurologic deficits, swelling and spasms of the urethra and bladder, joint swelling, chest tightness and pain, and renal colic (14, 15) . Laryngeal edema is the most serious complication and can become life threatening, but it is a relatively rare event. Only 0.9% of all edema episodes of HAE disease involved laryngeal edema (16) . In this study, symptoms such as swelling in the face, genitourinary region or extremities, and abdominal pain were present in our tested subjects. We found symptoms that might have been related to HAE in 39% of subjects. As mentioned above, the newly described clinical findings, such as headaches, described in the literature and outside the classic findings were not observed. A history of laryngeal edema development was not reported in our newly diagnosed patients. Symptoms appeared at an advanced age (median: 42 years) in our study population.
Although HAE is an autosomal dominant disorder, approximately 25% of disorders inherited in this manner may represent de novo mutations (17) . HAE is a genetically heterogeneous disease, with more than 100 C1 INH gene mutations described to date spanning all the exons and exon/intron boundaries (18) . However, genetic testing is rarely necessary, and, in fact, a negative test result cannot be used to exclude the diagnosis because new mutations that have not been previously identified are possible. In addition, a positive test result is consistent with the diagnosis but cannot be used to predict the natural history of the disease because the same genotypes present with various phenotypes (19) . Laboratory testing (complement testing: C4, C1 INH activity, and C1 INH antigen level) is needed to confirm or rule out the diagnosis of HAE (11, 20) . Even if a patient does not exhibit HAE symptoms, a confirmed diagnosis will allow them to prepare for the possibility of a future attack. The early diagnosis will also provide patients with the necessary education and knowledge to manage the HAE disorder during their daily life, including identification and avoidance of triggers and how to properly react to lethal complications, such as an airway obstruction (19) . In this study, 14/23 (61%) of the newly diagnosed subjects did not have any symptoms/signs suggestive of HAE in their past medical history until our survey. Proving their diagnosis of HAE during our study will let unscreened blood relatives be aware of the disease and prepare for a possible HAE attack in the future. Table 2 . Clinical, demographic and laboratory findings of screened untested relatives of HAE index patients morbidity and mortality, adverse events, and unnecessary surgical interventions (27, 28) . Especially, delayed treatment of laryngeal swelling can cause death (11, 13) . Zanichelli et al. (28) reported that the median age of the first symptoms was 12.0 years, and the corresponding median age at diagnosis was 24.3 years (29) . In our survey, the median age at diagnosis of untested blood relatives was too late (41 years). The median age at diagnosis was 42 years in symptomatic patients, and 17 years in asymptomatic patients.
Although HAE is inherited as an autosomal dominant disorder, it is known that testing family members and close/distant relatives for the disorder is not common practice worldwide. It is prudent to test family members or relatives of affected individuals to ensure appropriate education and treatment of HAE. This will decrease the time from the initial symptoms to diagnosis. Screening family members/ blood relatives for HAE may also be cost-effective by decreasing the number of physicians seen and the number of unnecessary tests and procedures ordered. Detecting the median age at diagnosis as 42 years in this study proves that screening/testing family members and close/distant blood relatives of these index patients for the HAE disorder must be a common practice. Ten out of 23 newly diagnosed patients (44%) were first-degree relatives of the index cases and 13/23 (57%) of them were more distant relatives. Of the subjects who enrolled in the study, 17 of them were first-degree relatives and 43 tested subjects were more distant relatives. The HAE diagnosis rate in first degree relatives was 59% (10/17), and it was at 30% (13/43) in the more distant (second and third degree) relatives (Table 2) .
CONCLUSION
This study shows us that screening untested close and distant family members for the HAE disorder is very prudent and should be done. Validating their diagnosis of HAE will let the untested relative subjects be aware of the disorder earlier in life and prepare for a possible HAE attack in the near future.
Key Messages HAE is a rare otosomal dominant disease caused by an inherited deficiency or dysfunction of the plasma protein C1 INH.
Despite its high probability of familial predisposition, many family members of HAE patients are not usually searched for the disease.
With new and effective therapeutic products, screening of family members has increasingly been given emphasis as a means to diminish the significant morbidity and mortality related to HAE.
Inappropriate treatment could result in higher morbidity and mortality, adverse events, and unnecessary surgical interventions. Especially, delayed treatment of laryngeal swelling can cause death.
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